TrialScope Tackles Issue of “Sharing Clinical Trial Results With Patients” at CBI Conference; Presents Sponsor Survey Findings
Jersey City, NJ-September 28, 2017-TrialScope, a global company in clinical trial transparency and compliance solutions, announced new findings from its sponsor survey on clinical trial results sharing practices, at CBI’s second annual Lay Summaries Summit in Philadelphia.
The survey asked sponsors about their current approach to trial results summaries and their plans for sharing summaries in the future. TrialScope’s Chief Strategy Officer, Thomas Wicks, presented highlights of the results in a session titled “How to distribute trial results summaries to patients?” on September 26th.
“There is a growing industry-wide understanding that patients have a right to receive information on the results of clinical trials in a language and format that is clear, concise, and factual,” said Wicks. “This is not only an evolving requirement, but also an opportunity to engage directly with trial participants and the patient community and make a difference in people’s lives.”
Key takeaways from the survey include:
· The sponsors that responded to the survey plan to provide up to 1,600 additional trial summaries to participants and patients in the coming 12 months
· 25 percent of those sponsors each plan to provide up to 6 new plain language summaries per month
· For sponsors that already share summaries, when asked why, 75 percent stated it is an important part of their “patient engagement efforts”
“ClinicalTrials.gov currently lists more than 250,000 trials from around the world,” continued Wicks. “It’s encouraging to see we’re headed in the right direction, but there is still progress to be made.”
About TrialScope
TrialScope simplifies the complexities of clinical trial transparency. TrialScope’s award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for sponsors that are responsible for over 35% of industry sponsored clinical trials posted on ClinicalTrials.gov. The company’s market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise, and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
